Novavax | NVAX - Assets


Novavax reported $1.18B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Adma Biologics USD 624.24M 55.56M Dec/2025
Agenus USD 226.8M 7.09M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
Cassava Sciences USD 118.35M 11.38M Dec/2025
Geron USD 570.54M 3.16M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
MannKind USD 792.18M 297.54M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Moderna USD 12.34B 203M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novavax USD 1.18B 3.38M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025